The tumor suppressor gene hypermethylated in cancer 1 (HIC1), which encodes a transcriptional repressor, is epigenetically inactivated in various human cancers. In this study, we show that HIC1 is a direct transcriptional repressor of the gene encoding ephrin-A1, a cell surface ligand implicated in the pathogenesis of epithelial cancers. We also show that mouse embryos lacking both Hic1 alleles manifest developmental defects spatially associated with the misexpression of ephrin-A1, and that overexpression of ephrin-A1 is a feature of tumors arising in Hic1 heterozygous mice in which the remaining wild-type allele is epigenetically silenced. In breast cancer, we find that ephrin-A1 expression is common in vivo, but that in cell culture, expression of the EphA receptors is predominant. Restoration of HIC1 function in breast cancer cells leads to a reduction in tumor growth in vivo, an effect that can be partially rescued by co-overexpression of ephrin-A1. Interestingly, overexpression of ephrin-A1 in vitro triggers downregulation of EphA2 and EphA4 levels, resulting in an expression pattern similar to that seen in vivo. We conclude that Hic1 spatially restricts ephrin-A1 expression in development, and that upregulated expression of ephrin-A1 resulting from epigenetic silencing of HIC1 in cancer cells may be an important mechanism in epithelial malignancy.
The tumor suppressor gene hypermethylated in cancer 1 (HIC1), which encodes a transcriptional repressor, is epigenetically inactivated in various human cancers. In this study, we show that HIC1 is a direct transcriptional repressor of the gene encoding ephrin-A1, a cell surface ligand implicated in the pathogenesis of epithelial cancers. We also show that mouse embryos lacking both Hic1 alleles manifest developmental defects spatially associated with the misexpression of ephrin-A1, and that overexpression of ephrin-A1 is a feature of tumors arising in Hic1 heterozygous mice in which the remaining wild-type allele is epigenetically silenced. In breast cancer, we find that ephrin-A1 expression is common in vivo, but that in cell culture, expression of the EphA receptors is predominant. Restoration of HIC1 function in breast cancer cells leads to a reduction in tumor growth in vivo, an effect that can be partially rescued by co-overexpression of ephrin-A1. Interestingly, overexpression of ephrin-A1 in vitro triggers downregulation of EphA2 and EphA4 levels, resulting in an expression pattern similar to that seen in vivo. We conclude that Hic1 spatially restricts ephrin-A1 expression in development, and that upregulated expression of ephrin-A1 resulting from epigenetic
Introduction
We first identified the tumor suppressor hypermethylated in cancer 1 (HIC1) in a region of chromosome 17p13 frequently targeted for allelic loss and CpG island hypermethylation in human cancer (Wales et al., 1995) . HIC1 resides within the critical deletion region associated with Miller-Dieker syndrome (MDS), a congenital disorder characterized by severe facial and neurological deficits Hirotsune et al., 1997) . Homozygous deletion of Hic1 in mice results in embryonic lethality with severe craniofacial and somatic defects similar to many of the abnormalities in MDS (Carter et al., 2000) , whereas Hic1 heterozygotes develop age-and gender-dependent tumors associated with promoter hypermethylation and gene silencing of the remaining wild-type allele (Chen et al., 2003) . These studies suggest that Hic1 has important roles in development and tumor suppression. However, the mechanisms behind this assumption have not been fully elucidated.
Hic1 is a sequence-specific transcriptional repressor with an N-terminal POZ domain, and five C2H2 zinc fingers at the C-terminus (Deltour et al., 1998 (Deltour et al., , 1999 (Deltour et al., , 2002 . Recent studies have demonstrated four transcriptional targets of Hic1, the class III histone deacetylase Sirt1 , the proneural bHLH transcription factor Atoh1 (Briggs et al., 2008) , the cell cycle and apoptosis regulator E2F1 ) and a G-protein-coupled receptor CXCR7 (van Rechem et al., 2009) . Importantly, deregulation of Sirt1 and Atoh1 in the absence of Hic1 function is associated with widespread effects in both development and tumor growth Briggs et al., 2008) . Furthermore, these data suggest that the identification of other genes regulated by Hic1 might better define the functional importance of Hic1 in development and epithelial tumor suppression.
Here, we define a role for HIC1 in the regulation of ephrin-A1, which encodes a cell surface ligand for Eph receptors. Eph receptors form the largest subfamily of receptor tyrosine kinases. Bidirectional ephrin/Eph signaling occurs in the context of cell-cell interactions and during the establishment of morphogenic boundaries in vertebrate development (Kullander and Klein, 2002; Pasquale, 2005 Pasquale, , 2008 . Ephrin-A1 is a glycophosphatidylinositol-linked EphA ligand that is frequently overexpressed in epithelial malignancies (Easty et al., 1999; Ogawa et al., 2000; Nakamura et al., 2005; Herath et al., 2006) . Recent studies show that overexpression of ephrin-A1 can promote tumor growth in vivo (BrantleySieders et al., 2006; Shi et al., 2008) . Using a combination of cDNA array analysis, ephrin-A1 expression studies and characterization of the ephrin-A1 promoter, we show here that Hic1 is a direct transcriptional repressor of ephrin-A1. In Hic1-deficient mouse embryos, widespread overexpression of ephrin-A1 is seen in epithelial tissues and the central nervous system. In breast cancer cells in which HIC1 is epigenetically silenced, in vivo growth can be blocked by restoration of HIC1 function, and then partially rescued by coexpression of ephrin-A1. On the basis of our findings, we propose that the misexpression of ephrin-A1 may be important in many of the morphological abnormalities seen in mice lacking Hic1, and that epigenetic silencing of HIC1 in cancer cells may constitute an important step in promoting the growth of breast cancer cells through upregulation of ephrin-A1 in vivo.
Results

Hic1 downregulates the expression of ephrin-A1
To search for potential transcriptional targets of HIC1 in carcinomas, we used an adenoviral vector AdHIC1 Briggs et al., 2008) to overexpress HIC1 protein in MCF-7 cells, a cell line in which HIC1 expression is epigenetically silenced by promoter hypermethylation (Wales et al., 1995) . Western blot analysis of cell lysates with a HIC1-specific antibody revealed sustained, high-level protein expression in response to AdHIC1 adenoviral infection over a 10-day period ( Figure 1a ). Immunofluoresence analysis of infected cells revealed that overexpressed HIC1 protein was readily detectable in the nucleus (Supplementary Figure  S1) . RNA from MCF-7 cells 9 h after infection with a control virus, or AdHIC1, was analyzed using the Affymetrix (Santa Clara, CA, USA) platform. Highly significant expression changes of more than twofold were seen in 70 genes, 58 of which were downregulated. Genes repressed by threefold or more are shown in Supplementary Table S1 . Although a number of important genes involved in cell growth and differentiation are represented, we pursued ephrin-A1 as the leading candidate based on its marked 23.4-fold repression, and the potential functional consequences of ephrin-A1 overexpression in both development and cancer.
Repression of ephrin-A1 steady-state mRNA expression by HIC1 was confirmed in separate experiments by real-time quantitative reverse transcriptase PCR in MCF-7 and MDA-MB231 cells, both of which are known to have marked hypermethylation of HIC1 (Wales et al., 1995) . As shown in Figure 1b , reexpression of HIC1 leads to 3.8-and 3.5-fold reduction of ephrin-A1 mRNA in MCF-7 and MDA-MB231 cells, respectively. In cell culture, previous studies show that ephrin- Hic1 regulates ephrin-A1 during tumorigenesis W Zhang et al A1 protein was expressed at extremely low levels in both MCF-7 and MDA-MB231 cells (Macrae et al., 2005) . To investigate whether HIC1 can repress ephrin-A1 expression at the protein level, we overexpressed HIC1 in two breast cancer cell lines, ZR-75-1 and MDA-MB453, in which HIC1 is epigenetically silenced, whereas ephrin-A1 is robustly expressed (Supplementary Figure S2 ). In both cell lines, overexpression of HIC1 leads to marked downregulation of endogenous ephrin-A1 protein within 48 h (Figure 1c ). To validate ephrin-A1 as a Hic1 transcriptional target in a more physiological condition, we examined ephrin-A1 expression in mouse embryonic fibroblasts (MEFs) derived from Hic1 þ / þ , Hic1 þ /À and Hic1 À/À mice. Knockout of Hic1 leads to 1.32-and 4.15-fold increase of ephrin-A1 mRNA in Hic1 þ /À and Hic1 À/À MEF cells, respectively (Figure 1d ). In addition, we used a small interfering RNA (siRNA)-based strategy to knockdown HIC1 in human WI38 cells as previously described . We found that the mRNA levels of ephrin-A1 increased by nearly threefold on HIC1 knockdown, compared with a nontarget siRNA control ( Figure 2 ). As aging Hic1 þ /À heterozygote mice develop carcinomas, sarcomas and lymphomas in which the remaining wild-type allele is silenced by promoter DNA hypermethylation (Chen et al., 2003) , we asked whether loss of Hic1 in these tumors was associated with increased expression of ephrin-A1. Of the eight tumors examined, six demonstrated membrane and cytoplasmic expression of ephrin-A1 in the absence of Hic1 expression (Supplementary Figure S3) . By contrast, a hemangiosarcoma (tumor 8), which was not hypermethylated at the wild-type Hic1 allele and that expressed Hic1 protein (Chen et al., 2003 , lacked ephrin-A1 protein expression (Supplementary Figure S3) . Only one of the eight tumors lacked both proteins. These results indicate that ephrin-A1 expression is downregulated by Hic1.
Hic1 is a sequence-specific transcriptional repressor of ephrin-A1 We next analyzed 7.9 kb from transcription start site of ephrin-A1 gene for consensus DNA-binding sites using the TRANSFAC search engine (Wingender et al., 2000) . Numerous transactivation sequences were identified within 2 kb of the transcription start site, including consensus binding sites for necrosis factor (NF)-kB and basic helixloop-helix transcription factors ( Figure 3a) . Analysis of the HIC1 consensus sequence demonstrated a total of eight binding sites, all between À4 to À8 kb from the transcription start site, and they are listed in Supplementary Table S2 and shown graphically in Figure 3a . No potential HIC1-binding sites were identified within the first 4 kb upstream of the transcription start site. Functional correlates of these findings were investigated using luciferase reporter assays. Four human ephrin-A1 promoter constructs ( Figure 3a) were created by subcloning the appropriate fragments into the pGL3-basic vector. Basal activity of these constructs, assessed by transient transfection in MCF-7 cells, showed that the ephrin-A1 promoter is highly active, with a twofold increase in activity observed with the inclusion of sequence containing the putative NF-kB-binding sites ( Figure 3a) .
Transient co-transfection experiments using an expression vector encoding wild-type HIC1 (pRcHIC1), and the ephrin-A1 reporter construct pEFNA1P8.3, showed that transfection of increasing amounts of pRcHIC1 in nanogram quantities resulted in repression of reporter gene activity ( Figure 3b ). Interestingly, this effect is lost with increases in the amount of HIC1 expression vector above 8 ng per well. This result suggests quenching of the repressive effect above this dose. We next compared the effects of wild-type HIC1 with mutant expression vectors lacking the N-terminal POZ domain (pRcDPOZ) or the C-terminal zinc fingers (pRcDZFM). As shown in Figure 3c , both mutant vectors failed to repress luciferase activity. These data suggest that both the C-terminal DNA-binding domain and the N-terminal POZ domain are required for the biological function of HIC1 in transcriptional repression of ephrin-A1. To confirm that the HIC1-binding sites identified in ephrin-A1 promoter were necessary for repression in this assay, we compared the ability of exogenous HIC1 to repress luciferase activity in the four promoter constructs depicted in Figure 3a . Our results Hic1 regulates ephrin-A1 during tumorigenesis W Zhang et al demonstrate that the eight HIC1-binding sites are required for full repression, and that the two reporter constructs that do not contain HIC1-binding sites do not respond to exogenous HIC1 (Figure 3d) .
To establish that endogenous Hic1 protein is present at the ephrin-A1 promoter, we performed chromatin immunoprecipitation assays in NIH3T3 cells, which robustly express Hic1 protein that can be easily immunoprecipitated Briggs et al., 2008) . Importantly, there is high similarity between the human and mouse ephrin-A1 promoters for positions of the Hic1-binding sites as shown in Figure 3a . The mouse promoter has nine sites from À4.0 to À8.0 kb and no sites within À2.0 kb from the transcription start site (Supplementary Table S2 ). Primers spanning 200-300 bp regions of the mouse ephrin-A1 promoter (Supplementary Table S3 ) were optimized for PCR using NIH3T3 genomic DNA (data not shown). PCR amplification at the predicted size occurred in several regions of the mouse ephrin-A1 promoter containing predicted Hic1-binding sites (primers C, D, E, F and G) (Figure 4) , demonstrating sequence-specific occupancy of the mouse ephrin-A1 promoter by endogenous Hic1 protein. Thus, the functional Hic1-binding sites identified in the mouse promoter are located approximately between À4 and À8 kb upstream of the transcription start site, which is consistent with the location of HIC1-binding sites in the human ephrin-A1 promoter identified by the promoter deletion analysis. Taken together, all the above data in this section show that Hic1 is a direct sequence-specific transcriptional repressor of ephrin-A1.
Misexpression of ephrin-A1 in Hic1-deficient mouse embryos Having identified and verified ephrin-A1 as a novel direct target for transcriptional repression by the tumor suppressor Hic1, we next examined in vivo correlates between Hic1 and ephrin-A1 in our Hic1-knockout mouse model. Homozygous embryos show a variable phenotype, ranging from severe craniofacial, neural and somatic disorders to minimal macroscopic defects (Carter et al., 2000) . We analyzed Hic1-knockout mice at E14.5 and compared them with wild-type littermates. In these embryos, we observed an overall increase in ephrin-A1 staining in Hic1-knockout embryos. An example of this overall increase in staining can be seen in midgestation embryos throughout the central nervous system (Figure 5a ). Some increased ephrin-A1 staining sites in the Hic1-knockout embryo, such as the forebrain, midbrain and skin, are correlated very well with the localization of Hic1 staining in a Hic1 þ /À embryo (Supplementary Figure S4) . In the developing parietal cortex of a Hic1 À/À embryo (Figure 5b ), abnormal expression of ephrin-A1 was observed in the cortical plate cells staining positive for Tuj1, a marker of early littermates. In summary, these data show that ephrin-A1 expression domains in mouse development are markedly expanded in mice lacking Hic1.
HIC1 inhibits tumorigencity of breast cancer cells partly through downregulation of ephrin-A1
Transcriptional regulation of ephrin-A1 has direct implications for HIC1 as a tumor suppressor. In cell culture, western blot analysis of lysates from MCF-7 and MDA-MB231 cells showed that ephrin-A1 protein was expressed at extremely low levels, whereas EphA2 and EphA4 proteins were readily detectable (Figure 6a ). Strikingly, when both cell lines are grown as xenografts in nude mice, we observed a marked decrease in EphA2 and EphA4 expression with a concomitant upregulation of ephrin-A1 expression (Figure 6a ). Expression of EphA2 and EphA4 was not influenced by adenoviral infection or overexpression of HIC1 in cell culture (data not shown).
In initial studies, we did not observe any changes in breast cancer cell growth or viability in response to HIC1 overexpression in vitro (Supplementary Figure  S5) , suggesting that an appropriate tumor-stromal/ endothelial cell interaction may be required for the tumor suppressor function of HIC1. In fact, in breast cancer, ephrin expression by epithelial cells is associated with reciprocal Eph receptor expression in adjacent vascular endothelial cells (Ogawa et al., 2000; BrantleySieders et al., 2006) . We hypothesized that this tumormicroenvironment signaling might be affected by HIC1 expression leading to downregulation of ephrin-A1 in cancer cells and suppression of tumor growth. Most studies assessing the effects of ephrin-A1 overexpression have used exogenous ephrin-A1-Fc. In contrast, we generated a recombinant adenovirus expressing human ephrin-A1 (AdEphrin-A1) (Supplementary Figure S6) , which allowed us to express ephrin-A1 in breast cancer cells. MDA-MB231 cells infected with AdEphrin-A1 virus showed robust expression of ephrin-A1, which led to 8.4-and 9.3-fold reduction of EphA2 proteins at 24 or 48 h after viral treatment, respectively. By contrast, overexpression of ephrin-A1 alone resulted in 3.2-and 3.9-fold decrease in the EphA4 protein level for the same time points (Figure 6b ). Cells infected with AdHic1, Adb-gal or AdEphrin-A1 were then injected subcutaneously into nude mice. After 5 weeks, the tumor volume analysis revealed a marked decrease in engraftment efficiency induced by overexpression of HIC1 (Po0.05), and a modest increase in tumor growth in response to ephrin-A1 overexpression (Po0.05; Figure 6c ). To test the contribution of ephrin-A1 downregulation to the tumor suppressor effect of HIC1 overexpression, we then coinfected cells with equal amounts of AdHIC1/Adb-gal or AdHIC1/AdEphrin-A1. As shown in Figure 6d , co-overexpression of ephrin-A1 partially restores the ability of MDA-MB231 cells to engraft nude mice, consistent with a positive role for ephrin-A1 as an important protein in engraftment and growth of breast cancer (Ogawa et al., 2000) , and with observations demonstrating that ephrin-A1 siRNA can block angiogenesis and metastasis in an in vivo model of breast cancer (Brantley-Sieders et al., 2006) . Together, these data support the notion that ephrin-A1 can be overexpressed in breast cancer in vivo when there is a loss of the transcriptional repression of HIC1 on the ephrin-A1 promoter.
Discussion
Using animal models, we have previously demonstrated that the transcriptional repressor Hic1 is not only a critical developmental regulator but also an epigenetically regulated tumor suppressor (Carter et al., 2000; Chen et al., 2003 Chen et al., , 2004 Chen et al., , 2005 Briggs et al., 2008) . In this study, we identified and characterized ephrin-A1 as another transcriptional target of Hic1. This finding has two important implications. First, we have previously shown that homozygous deletion of Hic1 in mice results in embryonic lethality with severe craniofacial and somatic defects. As the molecular mechanism underlying the developmental disorders has not been fully characterized, identification of ephrin-A1 as a new direct transcriptional target of Hic1 provides another explana- Hic1 regulates ephrin-A1 during tumorigenesis W Zhang et al tion for the functional importance of Hic1 in development. Second, cancer has been traditionally viewed as a genetic disease that is driven by the sequential accumulation of mutations, resulting in the loss of function of tumor suppressor genes or the constitutive activation of proto-oncogenes (Kinzler and Vogelstein, 1996; Hanahan and Weinberg, 2000) . However, it is now apparent that epigenetic gene silencing and associated promoter CpG island DNA hypermethylation constitute an alternative mechanism to mutations that inactivate tumor suppressor genes (Jones and Baylin, 2007; Esteller, 2008) . Given the high frequency of epigenetic silencing of HIC1 in most common human tumor types, and the high incidence of malignancies developed in Hic1 heterozygous mice, our data presented here reveal a potentially crucial role for HIC1 as tumor suppressor through the transcriptional regulation of ephrin-A1 signaling.
Ephrins and their receptors have a critical role in tissue patterning, morphogenesis, angiogenesis and neural development (Poliakov et al., 2004; Pasquale, 2005; Arvanitis and Davy, 2008) . Our data show that ephrin-A1 is misexpressed in Hic1-deficient mouse embryos, especially in the central nervous system, where abnormalities are often severe in this knockout model (Carter et al., 2000) . In light of the normally restricted expression pattern of ephrin-A1, the misexpression of this ligand seen in Hic1-knockout embryos is a striking finding, and suggests that Hic1 has an important role in coordinating development through transcriptional regulation of ephrin-A1. In addition, the broad specificity of ephrin-A1, which can bind to a wide range of EphA receptors, suggests that its misexpression could lead directly to the dramatic abnormalities in development in Hic1-deficient embryos through aberrant ephrin-A1 signaling. Hic1 regulates ephrin-A1 during tumorigenesis W Zhang et al Perhaps, the most important direct implication of our current data regards the role for HIC1 as a tumor suppressor gene, and a potential functional link to overexpression of ephrin-A1 in epithelial malignancies such as breast cancer. In fact, previous studies have shown that HIC1 is frequently hypermethylated and transcriptionally inactivated in breast cancer cell lines and primary tumors (Wales et al., 1995; Fujii et al., 1998) . Meanwhile, overexpression of both ephrins and Eph receptors has been observed in a variety of human malignancies (Easty et al., 1999; Tang et al., 1999; Takai et al., 2001) , including breast cancer (Ogawa et al., 2000) . Decreased protein expression of ephrin-A1 by an expression vector-based antisense RNA inhibited threedimensional growth of HT29 colon adenocarcinoma cells (Potla et al., 2002) . Importantly, a positive role for epithelial-specific ephrin-A1 in tumor initiation in vivo has also been demonstrated in the Apc min mouse model, in which overexpression of ephrin-A1 in enterocytes markedly enhanced the number of invasive tumors in both intestine and colon (Shi et al., 2008) . Furthermore, disruption of the ephrin-A1 receptor, EphA2, leads to increased susceptibility to chemically induced carcinogenesis in mouse skin, suggesting that EphA2 has tumor suppressor functions (Guo et al., 2006) . Together, these data suggest that ephrin-A1 exerts a positive role on tumorigenesis and ephrin-A1 receptor, EphA2, acts as a negative regulator of tumorigenesis. Our studies of breast cancer cells reveal a critical role of HIC1 in the regulation of tumorigenesis, at least partly through transcriptional repression of ephrin-A1. In a xenograft model, we demonstrate that restoration of HIC1 function in breast cancer cells leads to a significant reduction in tumor growth in nude mice, and importantly, co-overexpression of ephrin-A1 with HIC1 partially restores the ability of breast cancer cells to engraft nude mice, supporting a positive role of ephrin-A1 in promoting malignant cell growth in vivo. In contrast to these above data, other studies in breast cancer and prostate cancer cell lines have shown that EphA2 expression is a prominent feature in many of these systems, and that activation of EphA2 by an ephrin-A1-Fc fusion protein results in inhibition of the oncogenic Ras/MAPK signaling in several different cell types (Miao et al., 2001 (Miao et al., , 2009 Macrae et al., 2005) .
Three important issues might explain these contradictory findings. First, data supporting a positive role for ephrin-A1, including data presented here, have been performed in vivo, suggesting that cell lines in tissue culture may not represent the potential for non-cell autonomous signaling mediated by ephrin-A1 expressed on tumor cells. It has been well established that vascular recruitment by tumors is a critical step in tumorigenesis. A growing body of evidence demonstrates that upregulation of ephrin-A1 in breast cancer cells has been directly implicated in tumor angiogenesis, neovascularization and metastasis through cancer-specific expression of ephrin-A1, and reciprocal expression of EphA receptors in tumor stromal and endothelial cells (Brantley-Sieders et al., 2004 . For example, endothelial cells isolated from EphA2-deficient mice displayed defective ephrin-A1-induced migration in vitro and in vivo, and EphA2-deficient mice showed a diminished angiogenic response to ephrin-A1 in vivo (Brantley-Sieders et al., 2004) . Furthermore, siRNAmediated ephrin-A1 knockdown in metastatic mammary cancer cells leads to decreased lung metastasis in vivo (Brantley-Sieders et al., 2006) . Interestingly, a recent study showed that a functional and soluble form of ephrin-A1 is released from ectopic ephrin-A1-expressing glioblastoma multiforme cells and endogenous ephrin-A1 expressing breast cancer cells. The soluble ephrin-A1 may interact with EphA2 receptors on endothelial cells, and therefore provide a paracrine role for ephrin-A1 in stimulating angiogenesis . Here, we clearly show that in vivo, the ratio of ephrin-A1 to EphA2/4 expression is dramatically altered in favor of ephrin-A1 expression, supporting the notion that tumor-expressed ephrin-A1 interacts with EphA2 on endothelial cells to promote tumorigenesis via angiogenesis. Second, when ephrin-A1 is overexpressed by tumor cells either endogenously or ectopically, these cells exhibit downregulation of EphA2 (Macrae et al., 2005; Miao et al., 2009) . We have shown that overexpression of ephrin-A1 results in reduction of EphA2 and EphA4 expression in breast cancer cells, thus reducing the capacity for these receptors to signal. Downregulation of EphA2/4 in response to ephrin-A1 overexpression in tumor cells could provide a mechanism by which the tumor cells can circumvent quenching the released ephrin-A1 before it has a chance to exert a paracrine function on the endothelial cells within the tumor environment . Finally, ephrin-A1 can bind to all Eph receptors of the A subclass, and the receptor EphA2 binds ephrin-A1 with the highest affinity (Holder and Klein, 1999) . Therefore, the biological function of ephrin-A1 signaling during tumorigenesis is not limited to inhibition of Ras/MAPK signaling. For example, ephrin-A1-specific siRNA treatment can increase p21 expression in a hepatocellular carcinoma cell line (Iida et al., 2005) , suggesting that the balance between ephrin-A1 and EphA expression may have cell type-specific effects.
In summary, our studies support the concept that ephrin-A1 has a positive role in tumor growth in vivo, and are consistent with previous reports of ephrin-A1 acting through EphA receptors in the tumor microenvironment in vivo. Our data suggest a mechanism to explain how loss of Hic1 function may be a potentially important event in carcinogenesis through the activation of aberrant tumor-endothelial cell interactions mediated by ephrin-Eph signaling.
Materials and methods
Antibodies
Antibodies for immunofluorescence are ephrin-A1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA, sc-911) (1:1000) and Tuj1 (Covance, Princeton, NJ, USA, MMS-435P) (1:100); for immunohistochemistry, rabbit polyclonal HIC1 (1:100), as previously described Briggs et al., 2008) , and ephrin-A1 (Santa Cruz Biotechnology, sc-911) (1:200); and for western blot the antibodies are HIC1 (1:100), ephrin-A1 (Santa Cruz Biotechnology, sc-20719) (1:200), EphA2 (Santa Cruz Biotechnology, sc-924) (1:2000), EphA4 (Upstate, Billerica, MA, USA, 07-309) (1:1000) and GAPDH (Upstate, MAB374) 1:10 000.
cDNA array analysis Adenoviruses were prepared as described (He et al., 1998) . Total RNA was extracted from MCF-7 cells infected with either wild-type AdHIC1 or mutant HIC1 lacking POZ domain (AdDPOZ) as a control. The transduction efficiency in MCF-7 cells was 75-80% as determined by green fluorescent protein expression. Analysis of gene expression was performed according to standard protocols on an Affymetrix HGU95A chip.
Reverse transcriptase-PCR All RNA samples were quality controlled using a Biorad Experion Bioanalyzer (Bio-Rad Laboratories, Hercules, CA, USA), then subjected to DNase I treatment before reverse transcription. Real-time quantitative PCR studies were performed using QuantiTect SYBR Green Kit (Qiagen, Valencia, CA, USA). All quantitative calculations were performed using the DD Ct method. Primer sequences are listed in Supplementary Table S4 .
Luciferase reporter assays
Reporter gene assays were performed as previously described . We measured luciferase activity in a luminometer (BD Biosciences, San Jose, CA, USA) and transfection efficiency was normalized using the paired Renilla luciferase activity using the Dual Luciferase Reporter Assay system (Promega, Madison, WI, USA) according to the manufacturer's instruction. Further experimental details can be found in Supplementary Information (SI) Methods.
Chromatin immunoprecipitation
This was performed essentially as described (Briggs et al., 2008) using a rabbit polyclonal antibody to Hic1 to detect the presence of endogenous Hic1 at the mouse ephrin-A1 promoter. Details are provided in Supplementary Information (SI) Methods.
